base metals investing Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
base metals investing Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
base metals investing Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
base metals investing Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
base metals investing Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
base metals investing Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
base metals investing Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
base metals investing Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
base metals investing Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
VVC Exploration Corporation Announces Application For Management Cease Trade Order And Provides Financing Update
